The Andalusian Health Service (SAS) begins today Friday to vaccinate with a thirdwas doses of the messenger RNA vaccines (preferably the same as that administered previously) to the immunosuppressed patients that contemplates the update of the vaccination strategy approved on Wednesday in the Interterritorial Council after obtaining the approval of the Public Health Commission. This third dose, which sand will be administered at the usual vaccination points by appointment, it is intended for 13,678 patients.
Likewise, this third dose to people with hematopoietic stem cell transplantation (allo and autotransplantation). In the case of transplantation in the last two years, this additional dose of mRNA vaccine will be given if they had received the two-dose regimen after transplantation. The additional dose will be administered at leasts 28 days after receiving the second.
It is also indicated this third dose to patients treated with anti ‐ CD20 drugs, including rituximab, ocrelizumab, ofatumumab, obinutuzumab, ibritumumab tiuxetan, veltuzumab, and tositumomab. The additional dose should be administered during treatment (if possible 15 days before the corresponding medication cycle) or, given the long duration and immunosuppressive power of anti-CD20 drugs, patients will continue to be considered immunosuppressed for a period of 3 months for all anti-CD20 drugs. CD20, except for rituximab that will last 6 months, so that those who, once the treatment had been completed, would have received two doses of vaccine during the same would, therefore, be in the immunosuppression period andxplicited, candidates to receive that additional dose.